TaiRx, Inc. (TPEX:6580)

Market Cap	1.81B -21.5%
Revenue (ttm)	27.88M +239.0%
Net Income	-221.13M
EPS	-2.00
Shares Out	112.12M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	105,376
Average Volume	228,530
Open	16.55
Previous Close	16.55
Day's Range	15.55 - 16.55
52-Week Range	13.55 - 31.80
Beta	0.45
RSI	47.54
Earnings Date	Apr 17, 2026

About TaiRx

TaiRx, Inc. focuses on the development and commercialization of therapeutics for the treatment of cancer and other diseases. The company’s products under development include CVM-1118, an oral anti-cancer drug that is Phase II clinical trial. Its pre-clinical products comprise TRX-920, an oral delivery formulation; and TRX-105, a molecule developed for treating and alleviating symptoms of various colitis. The company also offers Zelnite, a drug that helps in treatment of selenium deficiency; and focuses on development of the nodal diagnostic dev...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6580

Financial Performance

In 2025, TaiRx's revenue was 27.88 million, an increase of 239.03% compared to the previous year's 8.22 million. Losses were -221.13 million, 59.3% more than in 2024.